News & Updates

For patients with hypertension and diabetes, longer time spent in blood pressure (BP) target range helps lower the risk of cardiovascular disease, according to a study.

A population-based retrospective study of Hong Kong patients with type 2 diabetes (T2D) finds that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a lower risk of ischaemic stroke, while use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a lower risk of atrial fibrillation (AF).

In the treatment of polycystic ovary syndrome (PCOS), the combination of metformin plus oral contraceptives appears to benefit women without obesity, inducing favourable effects on glucose metabolism with no further harm on lipid metabolism, according to the results of a meta-analysis.

Carnitine appears to be beneficial in the treatment of women with polycystic ovary syndrome (PCOS), with the drug helping improve ovulation, clinical pregnancy, insulin resistance, and body mass index, according to the results of a meta-analysis.

Sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) confer the greatest reduction in kidney and cardiovascular risks in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), according to a study.

A recent study has established the association of increased background parenchymal enhancement (BPE) with obesity, insulin resistance, leptin, and adiponectin in premenopausal women who are at high risk of breast cancer.

Behavioural weight-loss interventions, such as diet alone and diet plus physical activity (PA), induce a beneficial change in biomarkers of insulin resistance and cardiometabolic health in adults with overweight or obesity, reports a study. However, no additional benefit has been observed with the addition of moderate-intensity PA to a diet-only intervention.